399 - The evolution of Alzheimer's disease and dementia care | Gayatri Devi, M.D.

Episode Overview

• This episode challenges the traditional view of dementia and Alzheimer's disease as monolithic, all-or-nothing conditions, presenting them instead as highly heterogeneous spectrum disorders that must be managed with personalized, patient-specific care.
• The conversation traces the shifting scientific paradigm of Alzheimer's pathology, moving away from a pure "amyloid-first" hypothesis toward a complex cascade initiated by neuroinflammation and shaped by cognitive reserve.
• The discussion highlights critical diagnostic and treatment nuances, including the challenges of diagnosing high-functioning individuals, the clinical realities of monoclonal antibodies, the impact of hormone changes like menopause on the female brain, and the distinctions between conditions like Lewy Body Dementia and Parkinson's disease.
• This content is highly relevant for clinicians, patients, caregivers, and anyone interested in understanding modern, multi-modal strategies for preventing and treating cognitive decline.

Key Concepts

• Dementia as a Highly Heterogeneous Spectrum: Rather than being a binary diagnosis, cognitive decline exists on a vast spectrum influenced by cognitive reserve, genetics, and individual brain resilience. Two individuals with the same physical brain pathology can exhibit vastly different levels of daily cognitive function.
• The Modern Pathological Cascade: The classic model of Alzheimer's focused primarily on extracellular amyloid plaque deposition. Modern neuroscience recognizes a more complex sequence: early neuroinflammatory changes (often beginning decades before symptoms) initiate a process that leads to amyloid plaque deposition, intracellular tau tangles, and eventual synaptic loss and cognitive decline.
• Cognitive Reserve and Compensation: Individuals with high cognitive reserve can harbor extensive physical pathology without showing clinical symptoms. Because their brains utilize alternative neural networks to compensate for damaged areas, standard cognitive screening tools (like the MMSE or MoCA) frequently fail to detect early-stage decline in highly intelligent or professional populations.
• The "Alzheimer's Plus" Reality: Pure Alzheimer's disease is rare in clinical practice. Most patients present with a combination of Alzheimer's pathology alongside other contributing factors, such as cerebrovascular disease (silent micro-strokes), Lewy body pathology, TDP-43 proteinopathy, or mild hydrocephalus.
• Inorganic vs. Organic Information (Names vs. Nouns): Forgetting arbitrary, made-up labels like names (neologisms) is a normal, non-pathological evolutionary trait of the human brain, which is wired to retain organic, contextual information. In contrast, struggling to recall common nouns (like "chair" or "book") points to a decline in structured semantic memory and is clinically concerning.
• The Neuroprotective Role of Estrogen: Estrogen receptors are highly concentrated in key memory structures like the hippocampus, where the hormone actively promotes synaptic sprouting and brain plasticity. The abrupt loss of estrogen during menopause can mimic early-stage dementia symptoms, a condition termed Menopause-Related Cognitive Impairment (MRCI).
• The Biomarker vs. Clinical Symptom Debate: Up to 44% of cognitively normal 90-year-olds harbor amyloid plaques without exhibiting symptoms. Over-relying strictly on biomarkers to diagnose Alzheimer's risks turning healthy, asymptomatic individuals into "patients in waiting" who may suffer unnecessary anxiety and undergo risky interventions.
• The Mechanics and Risk of ARIA: Amyloid-Related Imaging Abnormalities (including ARIA-E for edema/swelling and ARIA-H for microhemorrhages/bleeding) are critical side effects of anti-amyloid monoclonal antibodies. These drugs strip amyloid not just from brain tissues but also from cerebral blood vessel walls, compromising vascular integrity—a risk that is significantly higher in carriers of the APOE $\epsilon4/4$ genotype.
• Neuromodulation via Transcranial Magnetic Stimulation (TMS): TMS uses localized magnetic fields to stimulate specific cortical areas (like the dorsolateral prefrontal cortex), boosting neural connectivity. This therapy helps keep cognitive circuits functional, bypassing physical damage caused by underlying disease pathology.
• Lewy Body Dementia (LBD) vs. Parkinson’s Disease: While both are alpha-synucleinopathies, LBD presents with early cognitive decline and widespread pathology, whereas Parkinson's typically begins with localized motor symptoms in the basal ganglia. Prescribing dopamine-boosting Parkinson's drugs to an LBD patient can severely worsen cognitive symptoms and trigger psychosis.
• Learned Non-Use in Cognitive Decline: When individuals experience early cognitive slips, they often instinctively withdraw from challenging situations to avoid embarrassment. This lack of stimulation causes the underutilized neural pathways to atrophy further. Active cognitive exercises can reverse this learned non-use and help recover lost function.

Quotes

• At 0:02:13 - "There really is a spectrum aspect to Alzheimer's and dementias... much like autism, it really can span the spectrum from very mild impairment that doesn't get worse to severe impairment that deteriorates rapidly." - Explains why dementia must be managed on an individual basis rather than using a standardized, one-size-fits-all approach.
• At 0:05:07 - "Alzheimer's is defined as a loss of synaptic connectivity that is driven by the presence of extra-neuronal amyloid plaques, intra-neuronal tangles, and increasingly, what we now know to be inflammation in the supporting microglial cells." - Provides the pathological definition of the disease, highlighting the critical role of neuroinflammation alongside traditional protein markers.
• At 0:06:24 - "You can have someone who has moderate pathology and even severe pathology, and they can still perform very well in many areas because they have good brain reserve... a resilience in their brain." - Highlights the concept of cognitive reserve, explaining why physical brain pathology does not always correlate directly with clinical impairment.
• At 0:09:34 - "We're beginning to understand that changes in the inflammatory pathways may predate amyloid deposition by quite some time." - Underlines the shift in scientific understanding toward neuroinflammation as an upstream trigger rather than a downstream consequence of amyloid.
• At 0:17:31 - "Many of these patients score a 30 or 29 or 28 [on the MMSE or MoCA] well along into their condition... because they are so adept, they have such great cognitive reserve." - Explains why standard, brief cognitive tests are insufficient for early detection in highly intelligent or professional populations.
• At 0:19:19 - "Names are inorganic bytes of information. Our brain is trained to remember things organically... A name is really a neologism, it's a made-up thing. It doesn't have very much meaning." - De-stigmatizes occasional word-finding and name-recall difficulties, explaining the neurological reason why arbitrary names are harder to retrieve than conceptual memories.
• At 0:27:17 - "I think [giving] an overarching stage... is very reductionist, simplistic, and does a disservice to both the patient and the family." - Explaining why physicians must evaluate different cognitive domains independently rather than assigning a single, global disease stage.
• At 0:34:00 - "Estrogen receptors co-localize in the brain, particularly in different parts of the brain that deal with memory, like the hippocampus... the presence of estrogen drives synaptic sprouting." - Detailing the biological mechanism by which estrogen supports memory and brain plasticity.
• At 0:35:01 - "I have patients in my practice who have been misdiagnosed with Alzheimer's disease and other dementias who really only turned out to have menopause-related cognitive impairment." - Warning about the diagnostic overlap between hormone-related cognitive decline and early-stage Alzheimer's.
• At 0:42:25 - "If you take all people in their 70s, community-dwelling people, and you image them, about 25% of us will have amyloid in our brain... by the time you get to 90, about 44% of us will have amyloid without symptoms." - Highlighting why the presence of amyloid plaques alone is insufficient to diagnose Alzheimer's disease.
• At 0:45:14 - "Otherwise, as the International Working Group very eloquently put it, you have a large population of 'patients in waiting'—people waiting to become patients, but maybe in the process changing their whole approach to living." - Cautioning against aggressively testing asymptomatic people for amyloid, which can induce immense anxiety without offering clear clinical pathways.
• At 0:47:31 - "So what if it takes two years to clear the plaque as opposed to a year and a half?... We can go at it slowly." - Explaining her customized, slow-titration dosing protocol for monoclonal antibodies to minimize the risk of brain swelling and bleeding.
• At 0:54:33 - "Because the drug had a greater than 40% incidence of abnormal brain bleeding and brain swelling as a result of the use of the drug, I developed a very, very slow titration protocol... The amyloid's been developing over decades in these patients; there's no reason to go in and quickly accelerate the dosing." - Explaining the clinical rationale behind her modified, safer protocol for high-risk patients.
• At 0:58:45 - "Amyloid deposited in the blood vessels of the brain... can sometimes cause a break in the continuity of the blood vessels... It disrupts the lining of the arteries and it causes leakage of initially fluid, and that's called edema (ARIA-E), and then eventually there's extravasation of actual blood... and that then causes ARIA-H or hemorrhage." - Detailing the precise physical mechanism of how monoclonal antibodies cause brain swelling and bleeding.
• At 1:02:20 - "To me, an elegant trial, quite frankly... would be taking your 'low, slow, early' approach... taking these high-risk patients that are in their 50s or 60s, who are probably 10 years away from clinical disease... treating them in a way that is very low, very slow, very safe, and asking the question: are we bending the course of their disease?" - Highlighting the missed opportunity in current clinical trial designs which fail to evaluate preventative, low-dose protocols in pre-symptomatic patients.
• At 1:04:47 - "I have a woman in her 70s... we started her on Leqembi... She eventually cleared the amyloid. I decided to do a tau scan; she no longer had tau... and clinically she's done remarkably well... There are some patients who respond dramatically." - Demonstrating that removing amyloid early can downstream clear tau pathology and yield substantial clinical recovery.
• At 1:08:46 - "TMS works by stimulating the brain using magnetic stimulation that then creates a small area of current just under the area of the coil... And the hope is that by that method, you're able to keep those circuits alive regardless of the pathology." - Explaining how neuromodulation bypasses physical brain damage to preserve cognitive networks.
• At 1:26:01 - "What I find most troubling in my practice is the number of patients with Lewy Body who get diagnosed as having Parkinson's and are treated with Parkinsonian medications... and that actually worsens their Lewy Body." - Highlighting the clinical danger of treating LBD with dopamine agonists.
• At 1:43:07 - "No more heterogeneous disease I can think of... than Alzheimer's disease. Because each person with Alzheimer's has their own private version of Alzheimer's disease... that is different from everyone else." - Emphasizing why a "one-size-fits-all" treatment approach fails in dementia care.

Takeaways

• Utilize a "low and slow" titration protocol when administering anti-amyloid monoclonal antibodies to high-risk patients (especially APOE $\epsilon4/4$ carriers) to minimize the risk of ARIA-E and ARIA-H.
• Expand clinical diagnostic evaluations beyond basic screens like the MMSE or MoCA for high-functioning individuals, opting for comprehensive, multi-hour neuropsychological testing to detect domain-specific deficits.
• Incorporate quantitative structural MRIs to measure regional brain volumes (such as the hippocampus and parietal lobes) alongside biomarker verification (CSF analysis or PET scans) to catch early changes.
• Consider Menopause-Related Cognitive Impairment (MRCI) as a differential diagnosis for women presenting with sudden midlife executive and memory issues, evaluating whether hormone replacement therapy is appropriate.
• Prioritize a "cocktail" approach to dementia management by combining pathology-targeting drugs with lifestyle adjustments, cardiovascular risk reduction, and neuromodulation therapies like Transcranial Magnetic Stimulation (TMS).
• Carefully differentiate between Lewy Body Dementia and Parkinson's disease by noting the chronological onset of cognitive versus motor symptoms and checking for the presence of a "pill-rolling" rest tremor, which is typical of Parkinson's but rare in LBD.
• Avoid prescribing dopamine-boosting medications to patients with Lewy Body Dementia, as these drugs can worsen cognitive symptoms, trigger psychosis, and cause severe confusion.
• Leverage minimally invasive skin biopsies of small cutaneous nerves to check for alpha-synuclein pathology, confirming a clinical diagnosis of LBD or Parkinson's.
• Actively address "learned non-use" in patients experiencing cognitive decline by engaging them in structured, targeted brain exercises that force the use of compromised pathways.
• Investigate and mitigate upstream systemic neuroinflammatory triggers in midlife, such as chronic viral loads (e.g., Varicella Zoster, Herpes Simplex) and oral issues like gingivitis, to help prevent the early pathological cascade.
• Reduce subdermal hematoma risks in dementia patients prone to falls by assessing whether a left atrial appendage closure device (e.g., Watchman) can safely replace systemic anticoagulant therapy for those with atrial fibrillation.